RT Journal Article SR Electronic T1 COVID-19 pediatric mortality rates are heterogeneous between countries JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.17.20196832 DO 10.1101/2020.09.17.20196832 A1 Nadia González-García A1 América Liliana Miranda-Lora A1 Juan Garduño-Espinosa A1 Javier T. Granados-Riverón A1 Jorge Fernando Méndez-Galván A1 Jaime Nieto-Zermeño A1 María F Castilla-Peón YR 2020 UL http://medrxiv.org/content/early/2020/09/19/2020.09.17.20196832.abstract AB Introduction Severe COVID-19 is infrequent in children, with a lethality rate of about 0.08%. This study aims to explore differences in the pediatric mortality rate between countries.Methods Countries with populations over 5 million that report COVID-19 deaths disaggregated data by quinquennial or decennial age groups were analyzed. Data were extracted from COVID-19 Cases and Deaths by Age Database, national ministries of health, and the World Health Organization.Results 23 countries were included in the analysis. Pediatric mortality varied from 0 to 12.1 deaths per million people of the corresponding age group, with the highest rate in Peru. In most countries, deaths were more frequent in the 0-4 years old age group, except for Brazil. The pediatric/ general COVID-19 mortality showed a great variation between countries and ranged from 0 (Republic of Korea) to 10.4% (India). Pediatric and Pediatric/general COVID mortality have a strong correlation with 2018 neonatal mortality (r=0.77, p<0.001 and r= 0.88, p<0.001 respectively), while it has a moderate or absent (r=0.47, p=0.02 and r=0.19, p=0.38, respectively) correlation with COVID-19 mortality in the general population.Conclusions There is an important heterogenicity in pediatric COVI-19 mortality between countries that parallels historical neonatal mortality. Neonatal mortality is a known index of the quality of a country’s Health System which points to the importance of social determinants of health in pediatric COVID-19 mortality disparities, an issue which should be further explored.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAl authors are researchers of the Hospital Infantil de Mexico Federico Gomez. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was an analyisis of public databases, so no IRB approval was requestedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in the websites cited in the manuscript https://osf.io/mpwjq/ https://www.argentina.gob.ar/salud/coronavirus-COVID-19/sala-situacion https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa https://www.gob.mx/salud/documentos/datos-abiertos-152127 https://covid19.who.int/